Brief: Seres Therapeutics And Nestlé Health Science Present Results From Ecospor Iv Phase 3 Study Of Vowst, For Prevention Of Recurrence Of C. Difficile Infection

Seres Therapeutics

08/05/2023 15:38

May 8 (Reuters) - Seres Therapeutics Inc  MCRB.O :
    * SERES THERAPEUTICS AND NESTLÉ HEALTH SCIENCE PRESENT
RESULTS
FROM ECOSPOR IV PHASE 3 STUDY OF VOWST™, A MICROBIOTA-BASED ORAL
THERAPEUTIC FOR PREVENTION OF RECURRENCE OF C. DIFFICILE
INFECTION, AT THE DIGESTIVE DISEASE WEEK (DDW) ANNUAL MEETING
    * SERES THERAPEUTICS INC - RESULTS FROM ECOSPOR IV ADD TO
DATA
FROM ECOSPOR III PHASE 3 STUDY AND TOGETHER SUPPORTED RECENT
VOWST FDA APPROVAL

Source text for Eikon:  ID:nBw4NCJnSa 
Further company coverage:  MCRB.O 

 ((Reuters.Briefs@thomsonreuters.com;))